SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| ANDERSON KERRII B | Director | 2026-08-17 | Open-market sell 10b5-1 | 3000 | $954K |
| Schechter Adam H | President & CEO, Director | 2026-08-11 | Open-market sell 10b5-1 | 4669 | $1.5M |
| Summy Amy B. | EVP, Chief Marketing Officer | 2026-08-04 | Open-market sell | 924 | $283K |
| Wilkinson Peter J | SVP, Chief Accounting Officer | 2026-08-03 | Open-market sell | 82 | $25K |
| Wilkinson Peter J | SVP, Chief Accounting Officer | 2026-08-03 | Option exercise | 1338 | $280K |
| Wilkinson Peter J | SVP, Chief Accounting Officer | 2026-08-03 | Open-market sell | 1338 | $414K |
| Kyle Kathryn W | EVP, Chief Legal Officer | 2026-07-02 | Open-market sell 10b5-1 | 92 | $26K |
| Vaughn Bryan T | EVP and President, Diagnostics | 2026-07-02 | Open-market sell 10b5-1 | 234 | $67K |
| Kyle Kathryn W | EVP, Chief Legal Officer | 2026-07-01 | Option exercise 10b5-1 | 256 | — |
| Kyle Kathryn W | EVP, Chief Legal Officer | 2026-07-01 | Tax withholding 10b5-1 | 73 | $21K |
| Vaughn Bryan T | EVP and President, Diagnostics | 2026-07-01 | Option exercise 10b5-1 | 327 | — |
| Vaughn Bryan T | EVP and President, Diagnostics | 2026-07-01 | Tax withholding 10b5-1 | 93 | $26K |
| Kyle Kathryn W | EVP, Chief Legal Officer | 2026-06-08 | Open-market sell 10b5-1 | 762 | $201K |
| Schechter Adam H | President & CEO, Director | 2026-05-11 | Open-market sell 10b5-1 | 5903 | $1.5M |
| Meltzer Jonathan C | EVP, Operations | 2026-03-27 | Open-market sell 10b5-1 | 839 | $224K |
| Wilkinson Peter J | SVP, Chief Accounting Officer | 2026-03-27 | Open-market sell 10b5-1 | 1633 | $436K |
| Bailey Megan D. | EVP, Pres, Central Labs & Intl | 2026-03-26 | Grant/award | 1184 | $0 |
| Bailey Megan D. | EVP, Pres, Central Labs & Intl | 2026-03-26 | Tax withholding | 481 | $129K |
| Caveney Brian J | EVP, Pres of ED, CMO & CSO | 2026-03-26 | Grant/award | 9304 | $0 |
| Caveney Brian J | EVP, Pres of ED, CMO & CSO | 2026-03-26 | Tax withholding | 4042 | $1.1M |
Fiscal period ending 2025-12-31 versus 2024-12-31 — view filing on EDGAR →
Meaningful balance-sheet improvement and near-term regulatory relief are offset by a broadening operational and cybersecurity risk profile. Debt reduction and PAMA/LDT regulatory reprieves materially ease the near-term financial and compliance picture, but new supply chain fragility, expanded third-party IT and HIPAA exposure, Fortrea spin-off liability risk, and DOJ national security data restrictions introduce substantive new headwinds. The net result is a mixed shift of moderate magnitude — the easing is real but concentrated in near-term items, while the worsening spans multiple distinct themes.
5 company-specific · 4 eased/removed · 1 common-mode
New specific risk: manufacturer discontinuations or recalls of reagents, test kits, instruments could impact costs, testing volume, revenue. Substantive operational risk addition.
Changes or disruption in services, supplies, or transportation provided by third parties have impacted, and could in the future materially impact, the Company’s operations and business. Despite…
New disclosure of unexpected claims, liabilities, or costs under Fortrea agreements escalates spin-off risk beyond prior tax-restriction discussion.
The Company might not be able to engage in certain desirable capital raising or strategic transactions as a result of the Spin-off and may not achieve its intended results. To preserve, for U.S.…
New reference to HIPAA security regulations indicates expanded regulatory exposure beyond payment card standards, suggesting broader healthcare data compliance obligations.
Risks Related to Technology and Cybersecurity Failure to maintain the security of customer-related information or compliance with security requirements could damage the Company’s reputation with…
PAMA freeze lifted in 2027 with capped reductions 2027-2029 and potential further reductions thereafter—escalates reimbursement pressure beyond prior year's open-ended 2027 timeline.
Risks Related to Regulatory and Compliance Matters Changes in payer regulations or policies, insurance regulations or approvals, or changes in laws, regulations, or policies in the U.S. or globally…
New national security compliance obligations added; DOJ Data Security Program restrictions on international data transfers introduced as material risk.
Failure of the Company or its third-party service providers to comply with national security, privacy and data security laws and regulations could result in fines, penalties and damage to the…
PAMA reductions frozen for 2026 and capped at 15% annually 2027-2029, versus prior $100M expected reduction in 2026. Material improvement in near-term reimbursement outlook.
Continued changes in healthcare reimbursement models and products (e.g., health insurance exchanges), changes in government payment and reimbursement systems, or changes in payer mix, including an…
Debt reduced from $6.2B to $5.2B; near-term obligations halved from $1.0B to $500M. Material improvement in leverage position and liquidity.
The Company’s level of indebtedness and debt service requirements could adversely affect the Company’s liquidity, results of operations, and business. At December 31, 2025, the indebtedness on…
FDA LDT rule was rescinded; prior year emphasized imminent May 2025 compliance deadline and increased enforcement risk. Current year reflects reduced near-term regulatory pressure.
U.S. FDA regulation of LDTs and regulation by other countries of diagnostic offerings could have a material adverse effect on the Company’s business. The Company’s diagnostic instruments, test…
Removal of third-party cybersecurity risk disclosure, including reference to prior AMCA incident, suggests risk has been resolved or is no longer material to investors.
Any cybersecurity incidents affecting the information technology systems of third parties that provide services to the Company could have a material adverse effect on the Company's operations. The…
Expanded scope to explicitly include third-party vendor and supply chain IT risks, regulatory/contractual liability exposure, and heightened emphasis on third-party failure consequences.
Failure in the information technology systems of the Company or its vendors and other third-party service providers, or newly acquired businesses, or delays or failures in the development and…
Labcorp disclosed its 2026 Investor Day event, reaffirmed full-year 2026 guidance, and provided long-term financial outlook through 2029 with compound annual revenue growth of 5–8% and adjusted EPS growth of 8.5–11.5%. While the disclosure includes forward-looking financial projections and strategic priorities, it is fundamentally an operational/strategic communication event rather than a discrete financial event (e.g., earnings release, debt issuance, or M&A). The Item 7.01 Regulation FD Disclosure classification and the company's explicit statement that the information "shall not be deemed 'filed'" under Section 18 indicate this is a voluntary disclosure of business strategy and outlook, not a material financial result or transaction. However, the long-term guidance and strategic roadmap would be material to investors assessing the company's growth trajectory and capital deployment strategy.
View raw filing on EDGAR →Megan D. Bailey's resignation as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026, is the principal disclosed action. While the filing also describes Brian J. Caveney's assumption of expanded responsibilities, the core event triggering the 8-K disclosure is Bailey's departure from a senior executive role. The departure of a named executive officer at this level is material to investors.
View raw filing on EDGAR →This is a clear earnings release for Q2 2026 disclosing quarterly financial results (revenue of $3.73 billion, diluted EPS of $3.64, adjusted EPS of $4.99) and updated full-year 2026 guidance with raised revenue growth and adjusted EPS ranges. The press release is attached as EX-99.1 and includes detailed consolidated results, segment summaries, and forward-looking guidance, which are hallmarks of an earnings disclosure under Item 2.02.
View raw filing on EDGAR →The filing discloses a Board declaration of a quarterly cash dividend of $0.72 per share, payable September 11, 2026, to stockholders of record as of August 28, 2026. This is a routine but material dividend distribution to shareholders, clearly fitting the dividend_distribution category. The disclosure is made via Item 7.01 (Regulation FD Disclosure) with a supporting press release.
View raw filing on EDGAR →The disclosure announces Labcorp's intention to release second quarter 2026 financial results on July 30, 2026, with a conference call and webcast to discuss results. The press release explicitly states "Labcorp to Announce Second Quarter Financial Results" and references the earnings press release and accompanying financial information that will be posted. This is a standard earnings announcement disclosure, material to investors as it provides notice of when quarterly financial results will be publicly disclosed.
View raw filing on EDGAR →This is a classic Item 5.07 disclosure reporting the final results of Labcorp's 2026 Annual Meeting of Shareholders. The filing details voting outcomes for three proposals: election of 11 directors to the Board, advisory approval of named executive officer compensation, and ratification of Deloitte & Touche LLP as independent auditor. The vote tallies (votes for, against, abstentions, and broker non-votes) are explicitly certified by the Inspector of Elections, which is the standard format for shareholder vote result disclosures.
View raw filing on EDGAR →